Neuroblastoma Pipeline Global Therapeutics Landscape Review H1 2015

Press Release   •   Aug 25, 2015 07:19 EDT

Neuroblastoma - Pipeline Review, H1 2015 Adds “Neuroblastoma - Pipeline Review, H1 2015” which provides an overview of the Neuroblastoma pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1, 2015 Pipeline Review of “Neuroblastoma” addition with 67 market data tables and 16 figures, spread across 308 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Ability Pharma, SL , Acetylon Pharmaceuticals, Inc., Advanced Accelerator Applications SA, Aeterna Zentaris Inc., Ampio Pharmaceuticals, Inc., APEIRON Biologics AG, Aptose Biosciences Inc., AstraZeneca Plc, Bellicum Pharmaceuticals, Inc., Bexion Pharmaceuticals, LLC., BioLineRx, Ltd., Bionucleon Srl, Cebiotex, S.L., Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Cleveland BioLabs, Inc., CureFAKtor Pharmaceuticals, LLC, DEKK-TEC, Inc., Errant Gene Therapeutics, LLC, F. Hoffmann-La Roche Ltd., Gamida Cell Ltd., Ignyta, Inc., Juno Therapeutics Inc., Lindis Biotech GmbH, MabVax Therapeutics Holdings, Inc., Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Netris Pharma S.A.S., Novartis AG, Novogen Limited, Pono Pharma, Progenics Pharmaceuticals, Inc., Recombio S.L, Sareum Holdings Plc, Shionogi & Co., Ltd., Sutro Biopharma, Inc., Teva Pharmaceutical Industries Ltd, Threshold Pharmaceuticals, Inc. and United Therapeutics Corp.

Drugs Profile Discussed in this Research:

1-B7, 31-F9, ABTL-0812, ACY-957, AMXT-1501 + eflornithine hydrochloride, APN-301, APN-311, ATM-3507, AZ-64, BACPT-DP, bevacizumab, BL-8040, BN-210, BPX-701, BXQ-350, CCT-137690, CCT-244747, CEB-01, Cell Therapy for GD2 Expressing Solid Tumors, Cell Therapy for Neuroblastoma, Cell Therapy to Target GD2 for Neuroblastoma, Cell Therapy to Target GD2 for Neuroblastoma, celyvir, CEP-28122, CFAKC-4, CFAKY-15, CG-1521, cVE-199, Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology, dinutuximab, Drugs to Activate Caspase 3 for Oncology, Edotreotide Labeled Yttrium 90, eflornithine hydrochloride, eh8B6, entrectinib, evofosfamide, firtecan pegol, FSEC, iobenguane sulfate I 131, irinotecan sucrosofate liposomal, JCAR-023, Lutathera, M-606, Monoclonal Antibody to Inhibit GD2 for Oncology, Monoclonal Antibody to Target CD3 for Neuroblastoma, Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom, Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma, Monoclonal Antibody to Target GD2 for Neuroblastoma, NCE-001, NTX-010, Oncolytic Virus for Oncology, P-937, paclitaxel albumin bound, pazopanib hydrochloride, pembrolizumab, Peptide to Inhibit HDAC for Neuroblastoma, perifosine, racotumomab, Recombinant Protein to Inhibit HDAC for Neuroblastoma, ribociclib, RKS-262, RNAi Oligonucleotide for Oncology, RNAi Oligonucleotides for Neuroblastoma, RSF-701, S-588410, SAR-020106, SF-1126, Small Molecule to Target Netrin-1 Ligand for Oncology, Small Molecules for Neuroblastoma, Small Molecules for Neuroblastoma, Small Molecules to Antagonize ALK for Oncology, Small Molecules to Inhibit Aurora and ALK Kinase for Oncology, Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology, SRX-2523, Stem Cells to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy, Syrbactins, TL-118, TPI-287, TR-100, TRBS-07, Trilexium, Vaccine for Neuroblastoma, Vaccine for Neuroblastoma, Vaccine for Neuroblastoma and Vaccine for Neuroblastoma

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license).


  • The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Explore More Research Report on cancer therapeutics Market.

Cancer has always being considered to be one of the dreadful diseases because of the deficiency in effective therapeutics. Every new day seems to be an opportunity for the researchers to find out a new reagent that can relieve the patients from the immense pain due to the malignant out growth. In fact the pharmaceutical industries have helped those inventions to reach out to the sufferers as fast as possible. Then only the invention will find its goal successfully: heal the mankind.

Thus various clinical trials of cancer therapeutics are being performed to bring the tremendous developments in to account. You might make the high prices to be the result of the new cancer treatment medicines entering the market. In recent years, the promising discoveries are being licensed as fast as possible such that it does not delay in reaching out to the ailing hands. You can also make this the sole reason for the pharmaceutical industry to reach its pinnacle during last few years.

Thus nowadays, you will find certain cancer diseased patients living up to many years even after being diagnosed with the deadly disease. In other words, it can also be confessed that doctors are ready to accept the new changes with cancer therapeutics that are arising in the pharmaceutical industry.

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries